Company Overview and News

25
Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva

2h channelnewsasia
Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers.
ATHTF REGN AMGN TEVA TEVVF ANTM SNY TEVJF GCVRZ NVS SAN CI SNYNF ANTX

25
Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva

2h reuters
LOS ANGELES (Reuters) - Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers.
ATHTF REGN AMGN TEVA TEVVF ANTM SNY TEVJF GCVRZ NVS SAN CI SNYNF ANTX

25
Exclusive: Express Scripts covers Amgen, Lilly migraine therapies, excludes Teva drug

3h channelnewsasia
LOS ANGELES: Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but is excluding a rival medication made by Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers.
ATHTF REGN AMGN TEVA TEVVF ANTM SNY TEVJF GCVRZ NVS SAN CI SNYNF ANTX

89
4 Strong Stocks to Buy That Double As Big Takeover Targets

2018-10-16 investorplace - 2
One of the quickest ways to make money in the stock market is through M&A. Acquisition premiums are usually in excess of 20%, so if you own stock in a company and that company gets acquired, you could easily make 20% or more in a day. The potential rewards from takeover stocks are compelling.
FOX REGN AMGN SODA KDP TWX NFLX FIZZ AMRN TWC SNY WMT TGT SFM KR AMZN T KO FOXA DIS

12
Roche Announces Positive Data on Breast Cancer Drug Kadcyla

2018-10-16 zacks - 2
Roche (RHHBY - Free Report) announced encouraging results from a phase III study, KATHERINE, on breast cancer drug, Kadcyla.
AMGN IMGN NVS CTRL

31
10 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targets And Dividends

2018-10-16 seekingalpha
October's top net gain "safer" Healthcare WallStar is AbbVie. Its projected 23% net gain was 2.3% better than Sanofi's, and 3.4% more than Grifol's result per analyst targets of 10/12/18.
AMGN GRFS GILD DGX MCK SNY MDT STE JNJ PRGO NVS ABBV ABBV

 
Cytokinetics Unveils Expanded Development Pipeline and Provides Key Updates on Late-Stage Clinical Research Programs at R&D Day

2018-10-16 globenewswire
Investigational New Drug Applications Recently Filed for Two New Cardiac Programs: Cardiac Troponin Activator and Cardiac Myosin Inhibitor Advance Toward Phase 1 Studies
4503 ALPMY AMGN ALPMF

3
Market Extra: This stock-market pullback probably has further to go: analysts

2018-10-15 marketwatch
The new mantra for investors this week may be good things come to those who wait.
UA AMGN UAA TRIP MRO CMG

6
Immune Design to Halt Cancer Vaccine Program, Shares Plunge

2018-10-15 zacks - 1
Shares of Immune Design Corp. (IMDZ - Free Report) fell about 33.7% after the company announced that it will discontinue its CMB305 cancer vaccine program following a review of its portfolio. Year to date, shares of the company have dropped 52.6% compared with the industry’s decline of 4.1%.
AMGN IMDZ

5
Top Ranked Income Stocks to Buy for October 15th

2018-10-15 zacks
Here are four stocks with buy rank and strong income characteristics for investors to consider today, October 15th:
AMGN AEP AB DLPH

1
A Company In Decline? The Case For/Against Affimed After Bad News

2018-10-14 seekingalpha
Affimed has built a technology platform focused on immune cell-engaging antibodies for therapeutic effect in oncology.
AMGN PFE BMY

17
AbbVie Settles With Novartis to Delay Humira Biosimilar in US

2018-10-12 zacks - 1
AbbVie, Inc. (ABBV - Free Report) announced that it has settled a litigation with Sandoz, the generic arm of Novartis (NVS - Free Report) , involving AbbVie’s blockbuster arthritis drug, Humira (adalimumab). The company has signed a non-exclusive licensing deal with Sandoz related to Novartis’ proposed biosimilar version of Humira, in the United States, Europe and other countries where AbbVie has intellectual property.
CBSH AMGN CBSHP NVS ABBV ABBV CBCB CHRS

10
Abbvie settles Humira patent disputes with Novartis unit

2018-10-11 reuters
(Reuters) - Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira.
AMGN NVS ABBV ABBV

36
The October Pause That Refreshes

2018-10-11 seekingalpha
The much-awaited correction is finally here; the question is who will step up to the plate and will actually use it as a long-term buying opportunity.
VRTX AMGN GEC GE BRK.A BIIB GOOGL AAPL CELG GNE MSFT SBUX MS INTC

13
J&J (JNJ) to Set the Ball Rolling for Pharma Q3 Earnings

2018-10-11 zacks
We expect Johnson & Johnson (JNJ - Free Report) , a healthcare bellwether, to beat expectations when it reports third-quarter 2018 results on Oct 16, before market open. In the last reported quarter, the company delivered a positive earnings surprise of 1.94%.
VRTX AMGN JNJ

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to AMGN / Amgen Inc. on message board site Silicon Investor.

Amgen Inc. (AMGN) Amgen Inc. (AMGN) Amgen Inc. (AMGN) AMGEN AMGEN AMGEN
CUSIP: 031162100